These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 19760952)
1. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinom. Han AR; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Hepatogastroenterology; 2009; 56(93):1111-6. PubMed ID: 19760952 [TBL] [Abstract][Full Text] [Related]
2. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Chen YK; Hsieh DS; Liao CS; Bai CH; Su CT; Shen YY; Hsieh JF; Liao AC; Kao CH Anticancer Res; 2005; 25(6C):4719-25. PubMed ID: 16334166 [TBL] [Abstract][Full Text] [Related]
3. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Ali SA; Amin DH; Abdelkhalek YI Jpn J Radiol; 2020 May; 38(5):472-479. PubMed ID: 32078123 [TBL] [Abstract][Full Text] [Related]
4. [Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein]. Chen Z; Liang H; Zhang X; Wang X; Chen W; Shi X; Yi C; Rao L Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1615-9. PubMed ID: 23174588 [TBL] [Abstract][Full Text] [Related]
5. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070 [TBL] [Abstract][Full Text] [Related]
7. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794 [TBL] [Abstract][Full Text] [Related]
9. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632 [TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736 [TBL] [Abstract][Full Text] [Related]
11. Whole-body F-18 FDG PET for hepatocellular carcinoma patients after interventional treatment. Cheng MF; Wu YW; Tzen KY; Huang YH; Yen RF Neoplasma; 2007; 54(4):342-7. PubMed ID: 17822325 [TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma. Cho E; Jun CH; Kim BS; Son DJ; Choi WS; Choi SK Turk J Gastroenterol; 2015 Jul; 26(4):344-50. PubMed ID: 26039005 [TBL] [Abstract][Full Text] [Related]
13. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190 [TBL] [Abstract][Full Text] [Related]
14. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351 [TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845 [TBL] [Abstract][Full Text] [Related]
16. [Evaluating efficacy of transcatheter arterial chemo-embolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT]. Zhao M; Wu PH; Zeng YX; Zhang FJ; Huang JH; Fan WJ; Gu YK; Zhang L; Tan ZB; Lin YE Ai Zheng; 2005 Sep; 24(9):1118-23. PubMed ID: 16159437 [TBL] [Abstract][Full Text] [Related]
17. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125 [TBL] [Abstract][Full Text] [Related]
19. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma. Wang XL; Li H; Wang QS; Zhang XL Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1087-91, 1095. PubMed ID: 16939890 [TBL] [Abstract][Full Text] [Related]
20. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]